Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
Yuemei Hu(Jiangsu Provincial Center for Disease Control and Prevention), Ningshao Xia(Xiamen University), Yue Huang(Fujian Medical University), Xingcheng Huang(Xiamen University), Xiaowen Hu(Xiamen University), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Feng-Zhu Zheng, Changlin Yang, Ya-Hui Wang-Jiang(Xiamen University), Qiu-Fen Zhang, Xia Zang, Kongxin Zhu(Xiamen University), Weijin Huang(National Institutes for Food and Drug Control), Jiali Quan(Xiamen University), Li Zhang(Sichuan University), Jun Zhang(University of Southern California), Yafei Li(First Affiliated Hospital of Sichuan Medical University), Kai Chu(Jiangsu Provincial Center for Disease Control and Prevention), Yingying Su(Nanjing Medical University), Donglin Liu, Shoujie Huang(Xiamen University), Zhaofeng Bi(Xiamen University), Qi Chen(Xiamen University), Han-Min Jiang, Ting Wu(University of California, Los Angeles), Ya Zheng(Xiamen University), Guang Sun(First Hospital of China Medical University)
Cited by 26
Related Papers
Recent Progress on the Versatility of Virus-Like Particles
|Vaccines|2020|171
Generation of RORγt+ Antigen-Specific T Regulatory 17 Cells from Foxp3+ Precursors in Autoimmunity
|Cell Reports|2017|129
Genome-wide Analysis Identifies Bcl6-Controlled Regulatory Networks during T Follicular Helper Cell Differentiation
|Cell Reports|2016|126
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
|Clinical Pharmacology & Therapeutics|2018|126